In preclinical pharmacokinetic studies, it has been evaluated for many of the various targeted NSCLC oncoprotein inhibitors whether they are a transported substrate for the ABCB1 and ABCG2 transporters, using knockout mice. The gene discussed is ABCB1; the disease is non-small cell lung carcinoma.